Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis P...

Related Keywords

Switzerland ,Russia ,Ukraine ,United States ,America ,Paula Schwartz ,Edna Kaplan ,Andreas Muehler ,Jens Kuhle ,Jessica Breu ,Daniel Vitt ,Immunic Inc ,Exchange Commission ,Rx Communications Group ,University Hospital Basel ,Nasdaq ,Prnewswire Immunic Inc Nasdaq ,Program In Relapsing Multiple Sclerosis Ongoing ,Sclerosis Centre ,Week Data ,First Half ,Patients Shows Improvements ,Consistent Throughout ,Overall Progressive Multiple Sclerosis Population ,All Subtypes ,Nfl Effect ,Neuroprotective Potential ,Brain Volume Data ,Cohort Expected ,Relapsing Multiple Sclerosis Ongoing ,Conference Call ,Held Tomorrow ,Senior Physician ,Neuroimmunology Unit ,Multiple Sclerosis Centre ,Chief Executive Officer ,Chief Medical Officer ,North America ,Vidofludimus Calcium ,Private Securities Litigation Reform Act ,Annual Report ,Investor Relations ,